Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01006070|
Recruitment Status : Completed
First Posted : November 2, 2009
Last Update Posted : March 21, 2012
|Condition or disease||Intervention/treatment|
|Multiple Myeloma||Procedure: kyphoplasty|
The UCSF Adult Hematology Program maintains a data base of all patients with a diagnosis of multiple myeloma seen in the Clinic. As patients are treated, relapse, receive new treatment, are transplanted, or pass away, these data are entered into this Multiple Myeloma Data Base (MMDB).
The MMDB will be expanded to include parameters to identify those patients with myeloma affecting the spine. A recruitment letter will be sent to all patients in the MMDB identified as having myeloma affecting the spine asking if they would be interested in participating in this study.
Patients who agree to participate in the study will be given an appointment to meet with Dr. Wolf or Dr. Martin to discuss the study and if willing, to sign the informed consent document. They will have an exam and history taken that includes fracture history.
Patients who have signed consent will be sent for thoracic-lumbar spine films (unless they had prior spine films taken within the last 3 months). Those with normal films will not be eligible to be enrolled to the study. Those with abnormal spinal films will then be sent for MRI of the spine, pulmonary function testing, and meeting with Dr. R. Yonge who will administer the various QOL tests described below.
All eligible established and new patients will be invited to participate in the prospective study. Patients who sign the informed consent will be included in the prospective study. A minimum of 25 patients with vertebral fractures and 25 patients without fractures, will be observed to measure the impact of fractures on health-related quality of life. Study enrollment will be complete when 25 patients without a new fracture and 25 patients with a new fracture treated by balloon kyphoplasty have been enrolled.
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||March 2011|
|Actual Study Completion Date :||March 2011|
U.S. FDA Resources
Patients with existing spinal fractures
Myeloma patients with documented x-ray evidence of spinal fractures.
Other Name: balloon kyphoplasty
Patients without spinal fractures
Myeloma patients with bony disease in the spine without existing fractures.
Other Name: balloon kyphoplasty
- Identify and prospectively study patients with myeloma affecting the spine, with or without compression fractures. Use standardized tools to assess health-related QOL, physical and respiratory function in these patients [ Time Frame: 1 year ]
- Measure: effect of pre-existing spinal fracture, prospectively measure effect of fractures and treatment on QOL, physical and respiratory function, and incidence of future fractures [ Time Frame: 1 year ]
- Identify x-ray predictors of future/pending vertebral fractures [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006070
|United States, California|
|San Francisco, California, United States, 94143|
|Principal Investigator:||Jeffrey Wolf, MD||University of California, San Francisco|
|Principal Investigator:||Sigurd Berven, MD||University of California, San Francisco|
|Principal Investigator:||Thomas Martin, MD||University of California, San Francisco|